FEATURED COMPANIES
- Amgen Inc.
- Company
- Eli Lilly
- F. Hoffmann-La Roche AG
- GlaxoSmithKline Plc
- Merck & Co. Inc.
The global osteoporosis drugs market grew at a CAGR of around 5% during 2015-2020. Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing different scans, such as X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Various drugs are currently available in different formulations, ranging from regular tablets to intravenous (IV) infusions, for alleviating the symptoms of osteoporosis. These drugs help restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures and improve the overall muscle strength of the patients.
The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide. Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years. Looking forward, the publisher expects the global osteoporosis drugs market to exhibit moderate growth during the next five years.
The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide. Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years. Looking forward, the publisher expects the global osteoporosis drugs market to exhibit moderate growth during the next five years.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global osteoporosis drugs market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product type and route of administration.Breakup by Product Type:
- Bisphosphonates
- Calcitonin
- Rank Ligand Inhibitor
- Parathyroid Hormone Therapy (PTH)
- Selective Estrogen Receptor Modulators (SERMs)
- Sclerostin Inhibitor
- Others
Breakup by Route of Administration:
- Oral
- Injectable
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.Key Questions Answered in This Report:
- How has the global osteoporosis drugs market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global osteoporosis drugs market?
- What are the key regional markets?
- What is the breakup of the market based on the product type?
- What is the breakup of the market based on the route of administration?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global osteoporosis drugs market and who are the key players?
- What is the degree of competition in the industry?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- Company
- Eli Lilly
- F. Hoffmann-La Roche AG
- GlaxoSmithKline Plc
- Merck & Co. Inc.
1 Preface3 Executive Summary10 Value Chain Analysis12 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Osteoporosis Drugs Market
6 Market Breakup by Product Type
7 Market Breakup by Route of Administration
8 Market Breakup by Region
9 SWOT Analysis
11 Porters Five Forces Analysis
13 Competitive Landscape
List of Figures
List of Tables
Note: Product cover images may vary from those shown
- Amgen Inc.
- Eli Lilly
- Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Radius Health Inc.
- Teva Pharmaceutical Industries Ltd.
- UCB S.A.
Note: Product cover images may vary from those shown
LOADING...
